Business Wire

New Clinical Data Support Nexodyn® AcidOxidizing Solution (AOS) To Reactivate the Physiological Healing Process of Chronic Wounds

Jaa

APR Applied Pharma Research sa (APR), the Swiss independent developer of science driven and patent protected healthcare products, today announces the publication in “Advances in skin & wound care” (April 2018) of the results of a clinical pilot study on the efficacy and tolerability of Nexodyn® AcidOxidizing Solution (AOS), a sprayable Active Cleanser with ancillary antimicrobial activity developed for acute and chronic wound management.

Results suggest how Nexodyn® AcidOxidizing Solution (AOS), thanks to its synergic and distinctive physico-chemical properties, could play a key role in the management of chronic wounds as it promotes effectively wound rebooting by creating the ideal microenvironment to sustain the physiological healing process and favoring an optimized lesion closure.

The pilot study was conducted with a prospective, single-arm design by Prof. Robert Strohal in Austria and engaged 30 patients with critically colonized or locally infected chronic leg ulcers of any origin. Along the study, Nexodyn® AcidOxidizing Solution (AOS) was applied on each leg ulcer at every dress change for 35 days together with a nonadherent gauze and a multi-purpose absorbent dressing.

By the end of the study period, treatment with Nexodyn® AcidOxidizing Solution (AOS) led to the full healing of 37% of the chronic wounds as well as to a significant decrease in wound size (P<.001). Moreover, thanks to Nexodyn® AcidOxidizing Solution (AOS) active cleansing properties, wound-associated infections were eliminated, together with a reduction in pH values and local bioburden covering the wound, whilst no reinfection of any examined wounds was observed during the study.

Based on the pilot study, it can be postulated that the application of Nexodyn® AcidOxidizing Solution (AOS) contributes to normalize the pH value of chronic wounds and influence positively biochemical reactions pivotal for rebooting physiological healing process.

Data also confirm Nexodyn® AcidOxidizing Solution (AOS) favorable safety and tolerability profile, especially relevant in chronic wounds, with no adverse events reported over the study duration, high levels of pain relief and comfort at application as well as wound-associated pain reduction.

Due to demographic changes in developed countries, chronic wound healing represents an emerging healthcare issue both from a clinical and social perspective: health care professionals agree that traditional therapeutic alternatives do not satisfactorily address the complex clinical picture.

According to a new market research, the Global Wound Cleanser Product market is anticipated to grow, from $1504.7 million in 2016 to $2171.4 million by 2023, growing at a CAGR of 5.4% (1)

“Nexodyn could fill the gap with the current demand from health care professionals and patients for a treatment option able to address the wound healing complexity” says Giorgio Reiner, Corporate R&D Director at APR – “as it offers the possibility to actively cleanse the wound, thus creating the ideal conditions for wound rebooting”.

As a science driven developer, APR is committed to provide a growing body of clinical evidence to further delineate Nexodyn® AcidOxidizing Solution (AOS) safety and efficacy profile as a wound rebooter.

Full publication “The Management of Critically Colonized and Locally Infected Leg Ulcers with an Acid-Oxidizing Solution: A Pilot Study” available at: https://journals.lww.com/aswcjournal/fulltext/2018/04000/The_Management_of_Critically_Colonized_and_Locally.5.aspx.

(1) Global Wound Cleanser Product Market – Analysis and Forecast (2016-2023) by BSI Research.

About Nexodyn® AcidOxidizing Solution (AOS)

Nexodyn® AcidOxidizing Solution (AOS) is a sprayable Active Cleanser with an ancillary antimicrobial activity developed for acute and chronic wound management.

A wide array of non-clinical experiments and clinical experiences and studies suggest Nexodyn® AcidOxidizing Solution (AOS) to perform as a Wound Rebooter by creating the ideal microenvironment to sustain the physiological healing process. Rebooting a wound, favoring an optimized lesion closure and ensuring a favorable safety and tolerability profile, is especially relevant with chronic wounds.

Developed based on APR’s proprietary and patented technology TEHCLO®, the product is a newly conceived solution with three main features: highly pure and stabilized hypochlorous acid (HClO >95% of free chlorine species), acidic pH (2.5 – 3.0) and high Reduction-Oxidation Potential (ORP >1.000 mV).

Nexodyn® AcidOxidizing Solution (AOS) is intended for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, vascular ulcers), post-surgical wounds, burns and other lesions.

As observed in non-clinical experiments and clinical experiences, Nexodyn® AcidOxidizing Solution (AOS) has synergic physico-chemical properties sustaining wound rebooting to the benefit of patients and HCPs who can rely on the reactivation of the physiological healing process concomitantly to protection and management of uncontrolled microbial growth. Nexodyn® AcidOxidizing Solution (AOS) shows favorable tolerability, with no pain exacerbation, for prolonged periods of use and across the wound healing continuum.

For more info, please visit: http://www.apr.ch/apr-pharma-products/medical-prescription/nexodyn-wound-healing/#nexodyn-formula

About APR Applied Pharma Research sa

APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR is currently focused on 2 (two) areas: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.

Contact information

APR Applied Pharma Research s.a.,
Paolo Galfetti (CEO)
T: +41 91 6957020 or email to paolo.galfetti@apr.ch

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

H.I.G. Capital Announces the Sale of KidsFoundation19.7.2018 22:50Tiedote

H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €21 billion of equity capital under management, announced today that one of its affiliates has entered a definitive agreement to sell the KidsFoundation Group (“KidsFoundation”), the Dutch market leader in childcare services, to Onex Corporation (“Onex”)(TSX:ONEX). Terms were not disclosed. Headquartered in Almere, the Netherlands, KidsFoundation provides high-quality childcare to nearly 30,000 children between the ages of six weeks and 12 years. H.I.G. created KidsFoundation in 2014 through the acquisition of assets from the estate of Estro Group. During H.I.G.’s ownership, the company has developed strongly with significant capital invested by H.I.G. to create a high-quality childcare offering. H.I.G. worked with KidsFoundation management to optimise the footprint of the company by exiting loss-making locations, introduce new IT systems to drive operational improvement and develop an internal M&

SIG Combibloc Group Holdings S.à r.l.: 2018 Second Quarter Results19.7.2018 19:01Tiedote

We are pleased to announce our quarterly conference call to discuss the results of SIG Combibloc Group Holdings S.à r.l. for the second quarter ended June 30, 2018. Date: Monday, July 23, 2018 Time: 15.00 CEST / 14.00 BST / 9.00 EDT The call information will be distributed on our secure site. If you would like access to our call, please contact investor.relations@sig.biz . Regards, SIG Combibloc Group Holdings S.à r.l. View source version on businesswire.com: https://www.businesswire.com/news/home/20180719005634/en/ Contact information SIG Combibloc Group Holdings S.à r.l. Jennifer Gough investor.relations@sig.biz

NEORIS Announces Creation of Innovation Labs Worldwide to Create a Smarter Future19.7.2018 18:32Tiedote

NEORIS, a global digital consulting services company, announced today it is consolidating the most innovative solutions it has developed in different geographies and allocating unprecedented resources to deploy a network of Innovation Labs worldwide. The main objective is to lay the foundation for the continuous development of disruptive solutions for its four core industries: Manufacturing, Financial Services, Healthcare and Telecommunications. Due to its disruptive nature, NEORIS decided that its first Innovation Lab should be housed in the Monterrey Digital Hub, which today is the first-of-its-kind as it is a space where entrepreneurs, companies, universities and investors converge to foster an ecosystem for Digital Transformation. The lab inaugurated in Monterrey, Mexico is the first of a series of Innovation Labs that will open in the different countries that NEORIS operates, and is a space where customers can experience emerging technologies through real-life scenarios. One such

CORRECTING and REPLACING Albar Capital Deploys FlexNOW19.7.2018 18:29Tiedote

Subhead of release should read: Out-of-the-Box Multi-Asset Execution Management System (instead of Easy-to-Install Multi-Asset Execution Management System). The corrected release reads: ALBAR CAPITAL DEPLOYS FLEXNOW Out-of-the-Box Multi-Asset Execution Management System FlexTrade (@FlexTrade) today announced that Albar Capital Ltd., a new hedge fund led by Javier Velazquez (formerly of Millennium Capital Partners LLP), is now trading equities and futures using FlexNOW, FlexTrade’s new execution management system. “The FlexNOW team was instrumental in solving several of our problems,” said Jason Ruder, Trader at Albar Capital. “Not only are they helping us with our compliance requirements, they are also responsive to requests that improve my workflow.” According to Rhyd Lewis, FlexNOW Product Manager, FlexNOW’s quick onboarding and easy installation process was critical for Albar Capital’s launch on 2 July. “We had no problem integrating FlexNOW with Albar’s portfolio and risk managemen

Full Core of Westinghouse Fuel Achieved at South-Ukraine Nuclear Power Plant Unit 319.7.2018 16:25Tiedote

Westinghouse Electric Company announced today that Ukraine’s State Enterprise National Nuclear Energy Generation Company (SE NNEGC) Energoatom’s South-Ukraine NPP Unit 3 near Yuzhnoukrainsk in Mykolaiv province was loaded with a full core of Westinghouse VVER-1000 fuel. This is the first unit in Ukraine to operate with Westinghouse VVER-1000 fuel assemblies as the sole fuel source. “Westinghouse began supplying fuel to Ukraine in 2005, when the first lead test assemblies were delivered to South-Ukraine Unit 3,” said Aziz Dag, vice president and managing director, Northern Europe. “We are proud to continue supporting Ukraine with their energy diversification by supplying a full core of Westinghouse VVER-1000 fuel to our customer, Energoatom.” Westinghouse currently supplies fuel to six of Ukraine’s 15 nuclear power reactors. Beginning in 2021, the number of reactors with Westinghouse fuel will increase to seven. “Westinghouse has made significant investments over the last several years

Seoul Semiconductor Delivers Its Innovative LED "SunLike" to U.S. Lighting Market19.7.2018 16:00Tiedote

Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a market leader in LED (light emitting diode) design and manufacturing, announced that its innovative LED “SunLike” is applied to brand new lightings to be launched by three lighting premium brands in U.S., Pure Edge Lighting, LEDRAbrands, Inc. and Elite Lighting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180719005377/en/ The product of LEDRAbrands, Inc., NU4RA-SUN, which applied SunLike of Seoul Semiconductor (Photo: Business Wire) Seoul Semiconductor supplies SunLike to pendant lighting for Pure Edge, a U.S. lighting solution company. It is applied to high-end lighting for museums and art galleries that require the highest color quality. The leading lighting design companies, LEDRAbrands, Inc. and Elite Lighting, apply SunLike to downlights and spotlights respectively. “We have selected Seoul Semiconductor’s innovative LED SunLike for our human centric lighting and believ

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme